[A22-04] Remdesivir (COVID-19) - Benefit assessment according to §35a Social Code Book V
Last updated 19.04.2022
Commission awarded on 18.01.2022 by the Federal Joint Committee (G-BA).
Immune system and infections
Adults with COVID-19 disease who do not require supplemental oxygen and are at increased risk of developing a severe course of COVID-19
- Vaccinated patients: added benefit not proven
- Unvaccinated patients: indication of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.